Is Cannabis Coverage Becoming the New Reefer Madness?

When major news organizations report on cannabis potency, cannabis use disorder, or legalization, readers deserve context—not fear-driven headlines.

That is the argument made by NORML Deputy Director Paul Armentano in a recent commentary criticizing what he describes as alarmist and one-sided cannabis coverage by The New York Times. The newspaper has focused heavily on rising THC potency and the number of Americans who reportedly meet the criteria for cannabis use disorder. But according to NORML, those stories leave out important facts about consumer behavior, medical cannabis patients, youth use, treatment admissions, and the benefits of regulated cannabis markets.

The concern is not that cannabis should be above criticism. Cannabis carries risks, and responsible journalism should examine them. The problem arises when those risks are presented without the evidence and context needed to understand them.

The Short Answer

NORML argues that recent cannabis coverage from The New York Times exaggerates concerns about high-potency products and cannabis use disorder while overlooking several important facts:

• Most consumers do not necessarily choose the strongest available products.

• People often consume smaller amounts when using higher-potency cannabis.

• Regulated markets can establish serving limits, testing requirements, labeling rules, and age restrictions.

• Medical cannabis patients may satisfy certain diagnostic criteria simply because they use cannabis regularly.

• Youth cannabis use has not increased following adult-use legalization.

• Cannabis-related treatment admissions have declined in recent years, according to federal data cited by NORML.

That does not mean cannabis is harmless. It means cannabis policy and public-health discussions should be based on balanced evidence instead of recycled reefer-madness narratives.

Concerns About “Stronger Marijuana” Are Not New

Warnings about increasingly potent cannabis may sound like a modern development, but NORML points out that similar headlines have appeared for decades. The New York Times was publishing stories about supposedly more powerful marijuana as far back as 1978.

Today’s regulated market undoubtedly offers products with a wide range of THC concentrations. Cannabis flower, concentrates, edibles, tinctures, and other products are not interchangeable. Each can have different potencies, serving sizes, onset times, and effects.

However, the mere availability of a high-potency product does not establish how most consumers use it.

According to research cited by NORML, people frequently adjust the amount they consume based on the product’s strength. This behavior is called “titration.” In plain English, when a product is stronger, an experienced consumer may use less of it.

That is not an argument for ignoring potency. Consumers need accurate labels, reasonable serving guidance, education, and safeguards. It is an argument for discussing potency honestly rather than treating THC concentration alone as proof of a public-health crisis.

Do High-Potency Products Dominate Legal Cannabis Markets?

The existence of cannabis concentrates does not mean concentrates represent the typical cannabis purchase.

NORML notes that sales data from legal states indicate that many consumers continue to prefer lower-potency products—particularly cannabis flower. Just as the existence of grain alcohol does not mean every person purchasing alcohol chooses the strongest bottle available, the presence of high-THC cannabis does not tell us what most adults consume.

A useful analysis should ask more specific questions:

• Which products are consumers actually purchasing?

• How much are they consuming per occasion?

• Are products accurately tested and labeled?

• Do consumers understand delayed onset and serving sizes?

• Are regulators enforcing age restrictions?

• Are adults receiving practical harm-reduction information?

Those questions produce a more meaningful public-health discussion than potency percentages presented without context.

Regulation Gives States Tools That Prohibition Does Not

One of the strongest arguments for legalization and regulation is not that cannabis is risk-free. It is that legal markets give governments the ability to manage identifiable risks.

States can require:

• Laboratory testing

• Accurate THC labeling

• Child-resistant packaging

• Defined serving sizes

• Product tracking

• Health and safety warnings

• Age verification

• Restrictions on advertising to minors

• Penalties for businesses that violate the rules

An illegal market offers few, if any, of these protections.

In Florida, where adults continue to debate the future of cannabis policy, this distinction matters. Prohibition does not eliminate cannabis products or consumer demand. It primarily determines whether those products are sold through accountable businesses or an unregulated underground market.

Responsible regulation gives policymakers the ability to establish standards and respond when those standards are violated.

Cannabis Use Disorder Statistics Require Context

Another central issue raised in NORML’s commentary involves cannabis use disorder, commonly abbreviated as CUD.

A person may receive a cannabis use disorder diagnosis after meeting at least two criteria from a larger diagnostic list. Those criteria can include tolerance and withdrawal—experiences that may occur with frequent or habitual use.

NORML argues that this framework can create misleading results when applied to medical cannabis patients. A patient using cannabis regularly under medical supervision might develop tolerance or experience symptoms after discontinuing use. Those facts alone do not necessarily establish that cannabis is damaging the patient’s life or that the patient has lost control over their consumption.

This creates an important question: Are statistics measuring harmful behavior, or are they sometimes counting expected physical responses among regular medical users?

NORML contrasts this treatment with diagnostic guidance for prescribed opioids, where tolerance and withdrawal occurring during appropriate medical treatment are not automatically counted toward an opioid use disorder diagnosis.

None of this means cannabis dependency cannot occur. It can, and anyone who feels that cannabis is interfering with work, relationships, finances, mental health, or daily responsibilities should take those concerns seriously and seek qualified help.

But public reporting should distinguish between physical dependence, frequent therapeutic use, and genuinely harmful patterns of behavior.

Federal Treatment Data Complicate the Cannabis-Crisis Narrative

If cannabis use disorder is rapidly becoming a widespread public-health emergency, one might expect cannabis-related treatment admissions to rise alongside it.

However, NORML cites federal substance-use treatment data showing that the percentage of Americans seeking treatment primarily for cannabis has declined over the past several years. The organization also notes that annual treatment admissions involving alcohol remain substantially higher.

These figures do not prove that cannabis causes no harm. They do show why dramatic claims require more scrutiny.

Diagnostic estimates, self-reported symptoms, treatment admissions, emergency-room visits, and population-level consumption data measure different things. Combining them into a single frightening narrative can create more confusion than clarity.

Good journalism should explain those distinctions to readers.

What Has Happened to Teen Cannabis Use After Legalization?

Protecting young people is frequently presented as a justification for maintaining cannabis prohibition. That makes youth-use trends one of the most important measures of legalization’s effects.

According to the evidence cited by NORML, adult-use legalization has not produced the predicted increase in adolescent cannabis consumption. National surveys have instead found youth marijuana use at historically low levels during the legalization era.

This does not mean prevention efforts are no longer needed. Cannabis products should remain restricted to adults, and young people deserve accurate, age-appropriate education about potential risks.

But the available evidence challenges the claim that regulating adult cannabis markets inevitably causes more teenagers to consume cannabis.

Moving cannabis sales from an illicit dealer to a licensed business—with identification checks, testing standards, packaging requirements, and regulatory oversight—may offer more protection than leaving the entire market underground.

Cannabis Journalism Should Inform, Not Frighten

Cannabis journalism does not need to become cannabis promotion. Reporters should investigate industry misconduct, questionable health claims, inaccurate testing, irresponsible marketing, impaired driving, problematic consumption, and failures by regulators.

But scrutiny must operate in both directions.

Journalists should also question claims made by prohibition advocates, place alarming statistics in context, explain the limitations of available data, and compare cannabis policies with the treatment of legal substances such as alcohol.

Selective reporting creates a distorted picture. When the media highlights every possible cannabis risk while minimizing evidence that contradicts the crisis narrative, readers receive advocacy disguised as neutral analysis.

The public deserves reporting that acknowledges both the risks of cannabis and the harms created by criminalization.

Why This Conversation Matters in Florida

Florida’s cannabis debate is shaped by political advertising, conflicting public-health claims, industry interests, and decades of prohibition-era messaging.

Floridians need reliable information to evaluate questions about legalization, medical access, consumer safety, criminal justice, and regulation. Alarmist coverage makes those decisions more difficult by replacing nuance with fear.

A productive cannabis policy should recognize several truths at the same time:

• Cannabis is not harmless.

• Adults can use cannabis responsibly.

• Some people experience problematic use and deserve support.

• Medical patients should not automatically be stigmatized as having a disorder.

• Regulation provides consumer protections unavailable under prohibition.

• Young people should be protected through education and enforced age restrictions.

• Arresting adults does not make cannabis disappear.

That is the balanced discussion Florida—and the rest of the country—needs.

The Bottom Line

Cannabis policy should be guided by evidence, not nostalgia for reefer madness.

Concerns about potency, dependency, and public health deserve serious examination. But those conversations must include consumer behavior, differences between products, medical use, treatment trends, youth-use data, and the regulatory advantages of legalization.

Suncoast NORML supports honest cannabis education and evidence-based reform. That means acknowledging genuine risks without exaggerating them—and challenging influential media organizations when their coverage fails to tell the whole story.

This article is based on commentary by NORML Deputy Director Paul Armentano. Read and support the original national NORML article: “Calling Out the New York Times’ Alarmist Cannabis Coverage.”

Frequently Asked Questions

Is cannabis stronger today than it was in the past?

Some modern cannabis products contain higher concentrations of THC than traditional flower. However, product strength varies considerably, and consumers may use smaller quantities when consuming stronger products.

What is cannabis titration?

Titration is the practice of adjusting the amount consumed according to a product’s potency and its effects. A person using a stronger product may consume less than they would of a lower-potency product.

What is cannabis use disorder?

Cannabis use disorder is a clinical diagnosis based on a person meeting a minimum number of defined behavioral or physical criteria. NORML argues that criteria such as tolerance and withdrawal can sometimes classify regular medical cannabis patients in misleading ways.

Has legalization increased teenage cannabis use?

National evidence cited by NORML does not show an increase in youth cannabis use attributable to adult-use legalization. Teen cannabis consumption has instead fallen to historically low levels in recent surveys.

Why regulate cannabis instead of prohibiting it?

Regulation allows governments to impose testing, labeling, packaging, serving-size, tracking, and age-verification requirements. Those consumer protections generally do not exist in an illegal market.